By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
JNJ's dividend is safe, but its high valuation and reliance on M&A for growth make it a risky investment. The talc litigation remains a significant risk.
Risk: Talc litigation overhang
Opportunity: Potential EPS growth from strategic M&A
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
All too often, dividend stories start with a beaten-down stock and a nervous question about whether the payout can survive. Johnson & Johnson (NYSE: JNJ) is the opposite case. The healthcare giant raised its dividend for the 64th year in a row, and the payout looks about as secure as any in the market. The complication is the stock: shares have climbed more than 60% over the past year and trade within a few percent of an all-time high, closing near $257 as of this writing.
So the question worth asking isn't whether the dividend is safe. It is probably about as safe as dividend stocks get. Instead, the question is whether the stock is still worth buying after a run like that.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
In April, Johnson & Johnson's board lifted the quarterly dividend 3.1% to $1.34 per share, or $5.36 a year. That was its 64th straight annual increase -- a streak that makes it a Dividend King, the name for companies that have raised their payout for at least 50 years (consecutively) running. At the current share price, the dividend yields about 2.1%.
More telling than the yield is how comfortably the company covers it. The $5.36 annual payout eats up only about 46% of the non-GAAP (adjusted) earnings Johnson & Johnson expects to earn this year, so there's room for the dividend to keep climbing even if profits flatten. Backing all of it is one of the strongest balance sheets anywhere: Johnson & Johnson is one of only two U.S. companies S&P rates AAA -- a notch above the U.S. government itself -- a distinction it shares only with Microsoft.
The obvious risk is the talc litigation that has weighed on the company for years. Johnson & Johnson still faces tens of thousands of lawsuits alleging its talc-based baby powder caused ovarian cancer. A judge rejected the company's proposed $10 billion settlement early last year, sending the claims back into the court system to be fought out at trial. That's a cash overhang and a steady source of unflattering headlines. But for a company that generates far more cash than it pays out and carries a top-tier balance sheet, it reads as a manageable liability rather than a threat to the dividend.
Here's why the stock has climbed so far: the fear that drove its discount has faded.
For a while, investors braced for a painful patent cliff. Stelara, which at its peak sold more than $10 billion a year, is losing sales fast to cheaper biosimilar competition; its revenue fell about 60% year over year to $656 million in the first quarter of 2026. But the rest of the drug portfolio is more than making up the difference.
Total revenue in the quarter still rose 9.9% to $24.1 billion, led by the innovative medicine segment. Cancer drug Darzalex climbed about 22% to nearly $4 billion, and Tremfya -- the immunology drug Johnson & Johnson is steering patients toward -- jumped 68% to about $1.6 billion. Newer additions like Caplyta, gained in last year's Intra-Cellular Therapies acquisition, are helping too.
Given this backdrop, management was confident enough to raise its full-year guidance, calling for adjusted earnings per share of about $11.55.
Overall, John & Johnson offers a safe and growing dividend, a drug business that's outgrowing its patent cliff, and litigation that looks contained.
A year ago, worries about talc and Stelara left Johnson & Johnson trading at a discount to the broader market. Today, at a price-to-earnings ratio of about 22 based on that guidance. With a valuation like this, the easy part of the return -- the piece that came from a depressed valuation working its way back to normal -- is probably alrady in the rearview mirror.
So, is the stock a buy?
Johnson & Johnson is a wonderful business and an excellent stock to own for durable, growing income. And long-term holders have no reason to sell. But for new money, I'd rather wait for a pullback -- or for a few more quarters of the pipeline growing into the price -- than pay a premium for a stock whose discount has already closed.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,679! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!
Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 14, 2026. *
Daniel Sparks and his clients do not have positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"JNJ remains an excellent hold for income but lacks compelling upside for fresh capital at current premium valuation."
JNJ's 64-year dividend streak and 46% payout ratio on $11.55 guided EPS remain rock-solid, backed by AAA balance sheet and Darzalex/Tremfya growth offsetting Stelara's 60% plunge. Revenue rose 9.9% in Q1 2026; the patent cliff narrative has largely played out. However, at ~22x forward P/E versus historical mid-teens and S&P 500 ~21x, the re-rating trade is exhausted. Talc litigation remains an open cash and headline risk with tens of thousands of cases still pending post-$10B settlement rejection. New money faces limited margin of safety after the 60% run-up to near all-time highs.
The article underplays pipeline risk: if Darzalex and Tremfya growth slows or new competition intensifies while talc verdicts escalate beyond expectations, the 22x multiple could quickly compress back toward 16-17x, erasing the recent outperformance.
"At 22x forward earnings, JNJ has exhausted its valuation expansion, leaving investors exposed to downside risk if the pipeline growth fails to sustain current momentum."
JNJ is currently a classic 'bond proxy' trap for new capital. Trading at ~22x forward earnings, the valuation implies a growth profile that the company's legacy pharmaceutical business struggles to sustain long-term. While the AAA balance sheet and dividend safety are indisputable, the market has priced in a perfect transition from the Stelara patent cliff to the Darzalex/Tremfya growth engine. At current levels, you are paying a premium for a defensive asset that lacks the upside beta of its peers. Unless you are strictly hunting for yield, the risk-reward ratio is unattractive; the stock is priced for perfection in an environment where litigation overhangs still create binary tail-risk events.
If JNJ successfully navigates the remaining talc litigation through a structured bankruptcy settlement, the removal of this 'litigation discount' could trigger a valuation re-rating that justifies current premiums.
"JNJ's dividend is safe, but the stock's 60% run has priced in the Stelara recovery; new buyers need to believe the pipeline sustains double-digit EPS growth, not just offsets the cliff."
JNJ's 64-year dividend streak is real and the payout is fortress-secure at 46% of adjusted earnings. But the article conflates two separate questions: dividend safety (genuine) and equity valuation (questionable). At 22x forward P/E on $11.55 EPS guidance, JNJ trades at a 15% premium to the S&P 500 despite mid-single-digit revenue growth. The Stelara cliff is being offset by Darzalex and Tremfya, but the article doesn't quantify whether this mix sustains mid-teens EPS growth or reverts to low-single digits. The talc liability is dismissed as 'contained,' but tens of thousands of unresolved claims create tail risk to both cash flow and balance sheet. The real issue: you're paying a growth multiple for a mature company.
If Darzalex and Tremfya maintain 20%+ growth for 3-5 years while newer assets like Caplyta scale, JNJ could justify 24-26x forward P/E and deliver 10-12% annual returns from here—and the dividend provides downside cushion that pure-growth stocks lack.
"Even with a safe dividend, JNJ's upside is capped unless the pipeline delivers materially, as the current price already prices in a recovery that could falter if Stelara declines and talc costs re-emerge."
JNJ's dividend is safe, but the article’s bullish tone overlooks the risk that the 'premium' multiple already reflects a rebound in expectations. With a ~257 share price and ~22x forward EPS (EPS guide ~$11.55), upside depends on sustained earnings growth, not multiple expansion alone. Stelara's biosimilar erosion is real and could accelerate; talc-related costs remain a potential cash burden; while Darzalex and Tremfya help, there’s no guarantee the pipeline offsets weakness. A higher-rate regime or softer medtech demand could compress valuations even as the dividend stays intact. In short, the headline dividend king story hides earnings-risk dispersion that may cap total return.
Bullish counterpoint: JNJ's AAA balance sheet, diversified pharma/healthcare exposure, and visible dividend growth still justify a premium; a beat or faster pipeline progress could re-rate the stock even if the headline risks materialize.
"JNJ's balance sheet creates accretive M&A optionality that the panel has ignored."
Claude correctly flags the growth-multiple mismatch, but all four underplay second-order M&A risk. JNJ's $50B+ net cash and AAA rating position it to acquire high-growth assets at 15-20x EBITDA, potentially resetting the narrative. Talc overhang actually helps here: it caps the valuation, creating cheaper optionality on deals that could lift EPS growth to high-single digits faster than organic pipeline alone.
"JNJ's M&A strategy is a high-risk gamble that likely masks underlying organic growth stagnation rather than solving it."
Grok, your M&A thesis ignores the 'conglomerate discount' trap. JNJ’s historical capital allocation has been mediocre; buying high-growth assets at 20x EBITDA often leads to massive goodwill write-downs when integration fails or pipeline assets underperform. Relying on M&A to solve a growth deficit isn't 'optionality'—it's a desperate pivot that usually destroys shareholder value. We need to see disciplined organic execution, not another expensive acquisition spree that further complicates the balance sheet and delays a valuation re-rating.
"JNJ's M&A risk hinges on deal size and historical execution pattern, not whether M&A itself is inherently value-destructive."
Gemini's conglomerate discount warning is empirically sound—JNJ's last major deals (Actelion, Xtandi co-development) underperformed expectations. But Grok's M&A optionality isn't desperate; it's rational capital deployment when organic growth is 4-6% and balance sheet capacity exists. The real question: does JNJ's track record of disciplined, smaller bolt-on acquisitions ($5-15B range) differ from the Actelion-scale blunders? If so, M&A could be accretive without requiring 'perfect' execution. Gemini assumes failure; Grok assumes competence. Evidence matters more than philosophy here.
"Grok's M&A optionality may be fragile; talc risk, higher debt costs, and integration hurdles could undermine any EPS uplift from deals."
Grok's talc-driven M&A optionality is optimistic; talc risk remains persistent, debt costs likely rise, and integration hurdles can erase any pro forma EPS gains, making M&A a brittle tailwind rather than a reliable EPS catalyst.
JNJ's dividend is safe, but its high valuation and reliance on M&A for growth make it a risky investment. The talc litigation remains a significant risk.
Potential EPS growth from strategic M&A
Talc litigation overhang